{"id":"individual-atg","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Serum sickness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG binds to and eliminates T cells, which are key drivers of immune-mediated rejection and autoimmune disease. By reducing circulating T lymphocytes, it prevents graft rejection in transplant recipients and suppresses pathogenic immune responses in autoimmune conditions. The mechanism involves both direct cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC).","oneSentence":"ATG (anti-thymocyte globulin) is a polyclonal antibody that depletes T lymphocytes to suppress immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:42.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in renal transplant recipients"},{"name":"Treatment of acute rejection episodes in transplant recipients"},{"name":"Aplastic anemia"}]},"trialDetails":[{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT05166967","phase":"PHASE3","title":"Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-01-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":204},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT06572462","phase":"PHASE2","title":"ATG Individualized Dosing Model in URD-PBSCT.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-31","conditions":"Cytomegalovirus Infections, Infection Reactivation, Stem Cell Transplant Complications","enrollment":30},{"nctId":"NCT02392312","phase":"","title":"Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2015-01-21","conditions":"Kidney Transplant Recipients","enrollment":950},{"nctId":"NCT04778618","phase":"PHASE2","title":"Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":63},{"nctId":"NCT05634915","phase":"PHASE4","title":"Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-20","conditions":"Hematopoietic Stem Cell Transplantation, Acute Leukemia","enrollment":90},{"nctId":"NCT02282514","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation for Stiff Person Syndrome (SPS)","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2014-10","conditions":"Stiff-Person Syndrome","enrollment":23},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT00176878","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Bone Marrow Failure Syndromes","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-06","conditions":"Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome","enrollment":10},{"nctId":"NCT01530555","phase":"PHASE2","title":"Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2008-04","conditions":"Acquired Aplastic Anaemia","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Individual ATG","genericName":"Individual ATG","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATG (anti-thymocyte globulin) is a polyclonal antibody that depletes T lymphocytes to suppress immune responses. Used for Prevention of acute organ rejection in renal transplant recipients, Treatment of acute rejection episodes in transplant recipients, Aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}